Abstract
The aim of the present study was to evaluate the therapeutic effect of the novel neuroprotective multitarget brain permeable monoamine oxidase inhibitor/iron chelating-radical scavenging drug, VAR10303 (VAR), co-administered with high-calorie/energy-supplemented diet (ced) in SOD1G93A transgenic amyotrophic lateral sclerosis (ALS) mice. Administration of VAR-ced was initiated after the appearance of disease symptoms (at day 88), as this regimen is comparable with the earliest time at which drug therapy could start in ALS patients. Using this rescue protocol, we demonstrated in the current study that VAR-ced treatment provided several beneficial effects in SOD1G93A mice, including improvement in motor performance, elevation of survival time, and attenuation of iron accumulation and motoneuron loss in the spinal cord. Moreover, VAR-ced treatment attenuated neuromuscular junction denervation and exerted a significant preservation of myofibril regular morphology, associated with a reduction in the expression levels of genes related to denervation and atrophy in the gastrocnemius (GNS) muscle in SOD1G93A mice. These effects were accompanied by upregulation of mitochondrial DNA and elevated activities of complexes I and II in the GNS muscle. We have also demonstrated that VAR-ced treatment upregulated the mitochondrial biogenesis master regulator, peroxisome proliferator-activated receptor-γ co-activator 1α (PGC-1α) and increased PGC-1α-targeted metabolic genes and proteins, such as, PPARγ, UCP1/3, NRF1/2, Tfam, and ERRα in GNS muscle. These results provide evidence of therapeutic potential of VAR-ced in SOD1G93A mice with underlying molecular mechanisms, further supporting the importance role of multitarget iron chelators in ALS treatment.
Similar content being viewed by others
References
Al-Sarraj S, King A, Cleveland M, Pradat PF, Corse A, Rothstein JD, Leigh PN, Abila B, Bates S, Wurthner J, Meininger V (2014) Mitochondrial abnormalities and low grade inflammation are present in the skeletal muscle of a minority of patients with amyotrophic lateral sclerosis; an observational myopathology study. Acta Neuropathol Commun 2:165–174. doi:10.1186/s40478-014-0165-z s40478-014-0165-z
Azzouz M, Hottinger A, Paterna JC, Zurn AD, Aebischer P, Bueler H (2000) Increased motoneuron survival and improved neuromuscular function in transgenic ALS mice after intraspinal injection of an adeno-associated virus encoding Bcl-2. Hum Mol Genet 9:803–811
Bar-Am O, Amit T, Kupershmidt L, Aluf Y, Mechlovich D, Kabha H, Danovitch L, Zurawski VR, Youdim MB, Weinreb O (2015) Neuroprotective and neurorestorative activities of a novel iron chelator-brain selective monoamine oxidase-A/monoamine oxidase-B inhibitor in animal models of Parkinson’s disease and aging. Neurobiol Aging 36:1529–1542. doi:10.1016/j.neurobiolaging.2014.10.026
Burattini S, Ferri P, Battistelli M, Curci R, Luchetti F, Falcieri E (2004) C2C12 murine myoblasts as a model of skeletal muscle development: morpho-functional characterization. Eur J Histochem 48:223–233
Capitanio D, Vasso M, Ratti A, Grignaschi G, Volta M, Moriggi M, Daleno C, Bendotti C, Silani V, Gelfi C (2012) Molecular signatures of amyotrophic lateral sclerosis disease progression in hind and forelimb muscles of an SOD1(G93A) mouse model. Antioxid Redox Signal 17:1333–1350. doi:10.1089/ars.2012.4524
Chen F, Sugiura Y, Myers KG, Liu Y, Lin W (2010) Ubiquitin carboxyl-terminal hydrolase L1 is required for maintaining the structure and function of the neuromuscular junction. Proc Natl Acad Sci U S A 107:1636–1641. doi:10.1073/pnas.0911516107
Combs DJ, D’Alecy LG (1987) Motor performance in rats exposed to severe forebrain ischemia: effect of fasting and 1,3-butanediol. Stroke 18:503–511
Cryan JF, Mombereau C, Vassout A (2005) The tail suspension test as a model for assessing antidepressant activity: review of pharmacological and genetic studies in mice. Neurosci Biobehav Rev 29:571–625
Dillon LM, Rebelo AP, Moraes CT (2012) The role of PGC-1 coactivators in aging skeletal muscle and heart. IUBMB Life 64:231–241. doi:10.1002/iub.608
Dobrowolny G, Aucello M, Molinaro M, Musaro A (2008) Local expression of mIgf-1 modulates ubiquitin, caspase and CDK5 expression in skeletal muscle of an ALS mouse model. Neurol Res 30:131–136. doi:10.1179/174313208X281235
Filali M, Lalonde R, Rivest S (2011) Sensorimotor and cognitive functions in a SOD1(G37R) transgenic mouse model of amyotrophic lateral sclerosis. Behav Brain Res 225:215–221. doi:10.1016/j.bbr.2011.07.034
Finck BN, Kelly DP (2006) PGC-1 coactivators: inducible regulators of energy metabolism in health and disease. J Clin Invest 116:615–622. doi:10.1172/JCI27794
Garbuzova-Davis S, Willing AE, Milliken M, Saporta S, Sowerby B, Cahill DW, Sanberg PR (2001) Intraspinal implantation of hNT neurons into SOD1 mice with apparent motor deficit. Amyotroph Lateral Scler Other Motor Neuron Disord 2:175–180. doi:10.1080/14660820152882179
Gifondorwa DJ1, Robinson MB, Hayes CD, Taylor AR, Prevette DM, Oppenheim RW, Caress J, Milligan CE (2007) Exogenous delivery of heat shock protein 70 increases lifespan in a mouse model of amyotrophic lateral sclerosis. J Neurosci 27:13173–13180. doi:10.1523/JNEUROSCI.4057-07
Golko-Perez S, Mandel S, Amit T, Kupershmidt L, Youdim MB, Weinreb O (2016) Additive neuroprotective effects of the multifunctional iron chelator M30 with enriched diet in a mouse model of amyotrophic lateral sclerosis. Neurotox Res 29:208–217. doi:10.1007/s12640-015-9574-4
Gurney ME (1997) The use of transgenic mouse models of amyotrophic lateral sclerosis in preclinical drug studies. J Neurol Sci 152(Suppl 1):S67–S73
Halon M, Kaczor JJ, Ziolkowski W, Flis DJ, Borkowska A, Popowska U, Nyka W, Wozniak M, Antosiewicz J (2014) Changes in skeletal muscle iron metabolism outpace amyotrophic lateral sclerosis onset in transgenic rats bearing the G93A hmSOD1 gene mutation. Free Radic Res 48:1363–1370. doi:10.3109/10715762.2014.955484
Handschin C, Rhee J, Lin J, Tarr PT, Spiegelman BM (2003) An autoregulatory loop controls peroxisome proliferator-activated receptor gamma coactivator 1alpha expression in muscle. Proc Natl Acad Sci U S A 100:7111–7116. doi:10.1073/pnas.1232352100
Ignjatovic A, Stevic Z, Lavrnic D, Nikolic-Kokic A, Blagojevic D, Spasic M, Spasojevic I (2012) Inappropriately chelated iron in the cerebrospinal fluid of amyotrophic lateral sclerosis patients. Amyotroph Lateral Scler 13:357–362
Ikeda K, Hirayama T, Takazawa T, Kawabe K, Iwasaki Y (2012) Relationships between disease progression and serum levels of lipid, urate, creatinine and ferritin in Japanese patients with amyotrophic lateral sclerosis: a cross-sectional study. Intern Med 51:1501–1508
Imon Y, Yamaguchi S, Yamamura Y, Tsuji S, Kajima T, Ito K, Nakamura S (1995) Low intensity areas observed on T2-weighted magnetic resonance imaging of the cerebral cortex in various neurological diseases. J Neurol Sci 134(Suppl):27–32
Ince PG, Shaw PJ, Candy JM, Mantle D, Tandon L, Ehmann WD, Markesbery WR (1994) Iron, selenium and glutathione peroxidase activity are elevated in sporadic motor neuron disease. Neurosci Lett 182:87–90
Ionescu A, Zahavi EE, Gradus T, Ben-Yaakov K, Perlson E (2016) Compartmental microfluidic system for studying muscle-neuron communication and neuromuscular junction maintenance. Eur J Cell Biol 95:69–88. doi:10.1016/j.ejcb.2015.11.004
Jeong SY, Rathore KI, Schulz K, Ponka P, Arosio P, David S (2009) Dysregulation of iron homeostasis in the CNS contributes to disease progression in a mouse model of amyotrophic lateral sclerosis J Neurosci 29:610-619
Kang C, Li Ji L (2012) Role of PGC-1alpha signaling in skeletal muscle health and disease. Ann N Y Acad Sci 1271:110–117. doi:10.1111/j.1749-6632.2012.06738.x
Kasarskis EJ, Tandon L, Lovell MA, Ehmann WD (1995) Aluminum, calcium, and iron in the spinal cord of patients with sporadic amyotrophic lateral sclerosis using laser microprobe mass spectroscopy: a preliminary study. J Neurol Sci 130:203–208
Kiaei M, Kipiani K, Chen J, Calingasan NY, Beal MF (2005) Peroxisome proliferator-activated receptor-gamma agonist extends survival in transgenic mouse model of amyotrophic lateral sclerosis. Exp Neurol 191:331–336. doi:10.1016/j.expneurol.2004.10.007
Kokić AN1, Stević Z, Stojanović S, Blagojević DP, Jones DR, Pavlović S, Niketić V, Apostolski S, Spasić MB (2005) Biotransformation of nitric oxide in the cerebrospinal fluid of amyotrophic lateral sclerosis patients. Redox Rep 10:265–270. doi:10.1179/135100005X70242
Kupershmidt L, Amit T, Bar-Am O, Youdim MB, Weinreb O (2012) Neuroprotection by the multitarget iron chelator M30 on age-related alterations in mice. Mech Ageing Dev 133:267–274
Kupershmidt L, Weinreb O, Amit T, Mandel S, Carri MT, Youdim MB (2009) Neuroprotective and neuritogenic activities of novel multimodal iron-chelating drugs in motor-neuron-like NSC-34 cells and transgenic mouse model of amyotrophic lateral sclerosis. FASEB J 23:3766–3779
Kwan JY, Jeong SY, Van Gelderen P, Deng HX, Quezado MM, Danielian LE, Butman JA, Chen L, Bayat E, Russell J, Siddique T, Duyn JH, Rouault TA, Floeter MK (2012) Iron accumulation in deep cortical layers accounts for MRI signal abnormalities in ALS: correlating 7 Tesla MRI and pathology. PLoS One 7:e35241
Liang H, Ward WF, Jang YC, Bhattacharya A, Bokov AF, Li Y, Jernigan A, Richardson A, Van Remmen H (2011) PGC-1alpha protects neurons and alters disease progression in an amyotrophic lateral sclerosis mouse model. Muscle Nerve 44:947–956. doi:10.1002/mus.22217
Lin J et al (2002) Transcriptional co-activator PGC-1 alpha drives the formation of slow-twitch muscle fibres. Nature 418:797–801. doi:10.1038/nature00904
Ludolph AC, Bendotti C, Blaugrund E, Hengerer B, Loffler JP, Martin J, Meininger V, Meyer T, Moussaoui S, Robberecht W, Scott S, Silani V, Van Den Berg LH (2007) Guidelines for the preclinical in vivo evaluation of pharmacological active drugs for ALS/MND: report on the 142nd ENMC international workshop. Amyotroph Lateral Scler 8:217–223. doi:10.1080/17482960701292837
Luo G, Yi J, Ma C, Xiao Y, Yi F, Yu T, Zhou J (2013) Defective mitochondrial dynamics is an early event in skeletal muscle of an amyotrophic lateral sclerosis mouse model. PLoS One 8:e82112. doi:10.1371/journal.pone.0082112
Mechlovich D, Amit T, Mandel SA, Bar-Am O, Bloch K, Vardi P, Youdim MB (2010) The novel multifunctional, iron-chelating drugs M30 and HLA20 protect pancreatic beta-cell lines from oxidative stress damage. J Pharmacol Exp Ther 333:874–882
Miyazaki K et al (2011) Disruption of neurovascular unit prior to motor neuron degeneration in amyotrophic lateral sclerosis. J Neurosci Res 89:718–728. doi:10.1002/jnr.22594
Nefussy B, Drory VE (2010) Moving toward a predictive and personalized clinical approach in amyotrophic lateral sclerosis: novel developments and future directions in diagnosis, genetics, pathogenesis and therapies. EPMA J 1:329–341. doi:10.1007/s13167-010-0027-0
Oba H et al (1993) Amyotrophic lateral sclerosis: T2 shortening in motor cortex at MR imaging. Radiology 189:843–846
Oshiro S, Morioka MS, Kikuchi M (2011) Dysregulation of iron metabolism in Alzheimer’s disease, Parkinson’s disease, and amyotrophic lateral sclerosis. Adv Pharmacol Sci 2011:378278–378286. doi:10.1155/2011/378278
Palamiuc L, Schlagowski A, Ngo ST, Vernay A, Dirrig-Grosch S, Henriques A, Boutillier AL, Zoll J, Echaniz-Laguna A, Loeffler JP, Rene F (2015) A metabolic switch toward lipid use in glycolytic muscle is an early pathologic event in a mouse model of amyotrophic lateral sclerosis. EMBO Mol Med 7:526–546. doi:10.15252/emmm.2014.04433
Pansarasa O, Rossi D, Berardinelli A, Cereda C (2014) Amyotrophic lateral sclerosis and skeletal muscle: an updates Mol Neurobiol 49:984-990 doi:10.1007/s12035-013-8578-4
Ripolone M, Ronchi D, Violano R, Vallejo D, Fagiolari G, Barca E, Lucchini V, Colombo I, Villa L, Berardinelli A, Balottin U, Morandi L, Mora M, Bordoni A, Fortunato F, Corti S, Parisi D, Toscano A, Sciacco M, DiMauro S, Comi GP, Moggio M (2015) Impaired muscle mitochondrial biogenesis and myogenesis in spinal muscular atrophy. JAMA Neurol 72:666–675. doi:10.1001/jamaneurol.2015.0178
Santillo AF, Skoglund L, Lindau M, Eeg-Olofsson KE, Tovi M, Engler H, Brundin RM, Ingvast S, Lannfelt L, Glaser A, Kilander L (2009) Frontotemporal dementia-amyotrophic lateral sclerosis complex is simulated by neurodegeneration with brain iron accumulation. Alzheimer Dis Assoc Disord 23:298–300
Schoneich C, Dremina E, Galeva N, Sharov V (2014) Apoptosis in differentiating C2C12 muscle cells selectively targets Bcl-2-deficient myotubes. Apoptosis 19:42–57. doi:10.1007/s10495-013-0922-7
Shibata N, Kawaguchi-Niida M, Yamamoto T, Toi S, Hirano A, Kobayashi M (2008) Effects of the PPARgamma activator pioglitazone on p38 MAP kinase and IkappaBalpha in the spinal cord of a transgenic mouse model of amyotrophic lateral sclerosis. Neuropathology 28:387–398. doi:10.1111/j.1440-1789.2008.00890.x
Spinazzi M, Casarin A, Pertegato V, Salviati L, Angelini C (2012) Assessment of mitochondrial respiratory chain enzymatic activities on tissues and cultured cells. Nat Protoc 7:1235–1246. doi:10.1038/nprot.2012.058 nprot
Villena JA (2015) New insights into PGC-1 coactivators: redefining their role in the regulation of mitochondrial function and beyond. FEBS J 282:647–672. doi:10.1111/febs.13175
Wang Q, Zhang X, Chen S, Zhang X, Zhang S, Youdium M, Le W (2011) Prevention of motor neuron degeneration by novel iron chelators in SOD1G93A transgenic mice of amyotrophic lateral sclerosis. Neurodegener Dis 8:310–321
Winkler EA, Sengillo JD, Sullivan JS, Henkel JS, Appel SH, Zlokovic BV (2013) Blood-spinal cord barrier breakdown and pericyte reductions in amyotrophic lateral sclerosis. Acta Neuropathol 125:111–120. doi:10.1007/s00401-012-1039-8
Winkler EA, Sengillo JD, Sagare AP, Zhao Z, Ma Q, Zuniga E, Wang Y, Zhong Z, Sullivan JS, Griffin JH, Cleveland DW, Zlokovic BV (2014) Blood-spinal cord barrier disruption contributes to early motor-neuron degeneration in ALS-model mice. Proc Natl Acad Sci U S A 111:E1035–E1042. doi:10.1073/pnas.1401595111
Wu Z, Puigserver P, Andersson U, Zhang C, Adelmant G, Mootha V, Troy A, Cinti S, Lowell B, Scarpulla RC, Spiegelman BM (1999) Mechanisms controlling mitochondrial biogenesis and respiration through the thermogenic coactivator. PGC-1 Cell 98:115–124. doi:10.1016/S0092-8674(00)80611-X
Zhao Z, Nelson AR, Betsholtz C, Zlokovic BV (2015) Establishment and dysfunction of the blood-brain barrier cell 163:1064-1078 doi:10.1016/j.cell.2015.10.067
Zheng H, Youdim MB, Weiner LM, Fridkin M (2005a) Novel potential neuroprotective agents with both iron chelating and amino acid-based derivatives targeting central nervous system neurons. Biochem Pharmacol 70:1642–1652
Zheng H, Youdim MB, Weiner LM, Fridkin M (2005b) Synthesis and evaluation of peptidic metal chelators for neuroprotection in neurodegenerative diseases. J Pept Res 66:190–203
Zhong Z et al (2009) Activated protein C therapy slows ALS-like disease in mice by transcriptionally inhibiting SOD1 in motor neurons and microglia cells. J Clin Invest 119:3437–3449. doi:10.1172/JCI3847638476
Zlokovic BV (2011) Neurovascular pathways to neurodegeneration in Alzheimer’s disease and other disorders. Nat Rev Neurosci 12:723–738. doi:10.1038/nrn3114
Acknowledgments
The authors are grateful to Prize 4 Life, Inc. (Berkeley, CA) and Rappaport Family Research, Technion Israel Institute of Technology for their support.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of Interest
MBH Youdim is the scientific founder of Abital Pharma Pipelines and commercial interest in VAR10303 drug.
Rights and permissions
About this article
Cite this article
Golko-Perez, S., Amit, T., Bar-Am, O. et al. A Novel Iron Chelator-Radical Scavenger Ameliorates Motor Dysfunction and Improves Life Span and Mitochondrial Biogenesis in SOD1G93A ALS Mice. Neurotox Res 31, 230–244 (2017). https://doi.org/10.1007/s12640-016-9677-6
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12640-016-9677-6